Received small molecule targeted therapy such as TKIs within  weeks prior to study enrollment
Current use of systemic immunosuppressant(s), or prior anti-cancer therapy to include: lenalidomide, fludarabine, or alemtuzumab within  months; radioimmunoconjugate within  weeks; mAb or antibody-drug conjugate within  weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within  weeks prior to Day  of Cycle 
Any chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks of the first dose of mRNA- or pembrolizumab
Radiotherapy, chemotherapy, or targeted small-molecule therapy within  weeks prior to Day  of Cycle .
Patient has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day 
Current use of systemic corticosteroids greater than (>)  mg prednisone per day (or equivalent), or prior anti-cancer therapy to include: radioimmunoconjugate within  weeks; mAb or antibody-drug conjugate within  weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within  weeks prior to Day  of Cycle 
Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy or radiation therapy within  weeks prior to trial Day  as well as current participation or recipient of treatment on a clinical trial within  days prior to Day ;
Monoclonal antibody based anti-cancer therapy within  days prior to study entry or small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within  days prior to study entry.
Has had prior chemotherapy or targeted small molecule therapy within  weeks before administration of study treatment.
No concurrent chemotherapy or targeted small molecule therapy
Has had prior chemotherapy, targeted small molecule therapy, monoclonal antibody therapy, or radiation therapy within  weeks prior to on-study date\r\n* Note: If currently receiving hormonal therapy or chemotherapy, this treatment must be stopped at least  weeks prior to on-study date; hormonal therapy may be restarted after the restaging scan  month after the th BATs infusion\r\n* Note: Radiation therapy to the axial skeleton must be completed at least  weeks prior to on-study date
Patients who have received chemotherapy, small molecule targeted therapy or radiation within the  weeks of first dose of study drugs
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy for the current diagnosis of EGC
Has had any prior chemotherapy, targeted small molecule therapy, or radiation therapy for the currently diagnosed cancer
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study day  and who have not recovered adequately from this treatment (=< grade  toxicity at the time of enrollment)
Tumor with mutation that is known to be sensitive to FDA approved targeted therapy but has not yet received such targeted therapy
Has had any prior chemotherapy, targeted small molecule therapy, or radiation therapy for their current diagnosis
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy.
Have received targeted small molecule therapy <  days prior to CD;
Liver tumor-directed therapy, hepatic surgery, antibody-based therapy, or immunotherapy must not have been performed <  days, chemotherapy <  days, and targeted small molecule therapy or hormonal therapy <  days prior to enrollment.
Liver tumor-directed therapy, hepatic surgery, antibody-based therapy, or immunotherapy must not have been performed <  days, chemotherapy <  days, and targeted small molecule therapy or hormonal therapy <  days prior to enrollment. No radiation to tumor sites during the last  weeks.
Prior therapy including chemotherapy, targeted small molecule therapy or radiation therapy =<  weeks prior to registration OR failure to recover (to =< grade  or to baseline) from adverse events (AE) attributable to agents received >  weeks prior to registration; NOTE: exception for neuropathy =< grade , which is allowed
At least  weeks should have elapsed since the last treatment (e.g. chemotherapy, targeted small molecule therapy, immunotherapy or radiation) and must have recovered to grade  or better from the acute effects of prior therapy
Prior chemotherapy or targeted small molecule therapy within  weeks prior to study Day  or prior radiation therapy within  weeks prior to study Day .
Chemotherapy, targeted small molecule therapy, or radiation therapy within at least  weeks
At least  weeks from end of targeted therapy
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to Study Day 
Prior chemotherapy or targeted small molecule therapy within  weeks before administration of study treatment.
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to first dose of study drug
Has had prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to the planned first dose of the study
Chemotherapy, biologic therapy (antibodies and biologically targeted small molecules)
Received any anti-cancer therapy including chemotherapy or radiotherapy, steroid therapy for anti-neoplastic intent, and investigational therapy, including targeted small molecule agents within  days prior to the first dose of study drug or has not recovered to less than Grade  clinically significant adverse effect(s)/toxicity(s) of the previous therapy
Prior monoclonal antibody within  weeks prior to study Day  or chemotherapy, targeted small molecular therapy, or radiation therapy within  weeks prior to study Day 
Prior chemotherapy, targeted small molecule therapy, or radiation therapy within  weeks prior to study Day 
Treatment with a single course of gefitinib(Iressa) or erlotinib (Tarceva), or other small molecule or targeted therapies, or monoclonal antibody therapy (excluding docetaxel) will be considered and count as prior chemotherapy.
Biologic or other approved molecular targeted small molecule inhibitors should be washed out  week before apheresis and must be completed at least  week prior to pre-infusion lymphodepletive chemotherapy.
Prior chemotherapy, targeted small molecule therapy, or radiation therapy for current diagnosis of sarcoma
Current use of systemic corticosteroids greater than (>)  milligrams (mg) prednisone per day (or equivalent); or prior anti-cancer therapy to include: radioimmunoconjugate within  weeks; mAb or antibody-drug conjugate within  weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within  weeks prior to Day  of Cycle 
Treatment with chemotherapy or biological therapy within the previous  weeks, radiation or small molecule targeted therapy within the previous  weeks.
Have evidence of persistent, recurrent, or progressive disease for which there is no known or established treatment available with curative intent, after at least one course of systemic therapy for locally advanced or metastatic disease , including chemotherapy, targeted therapy (small molecule or antibody based), or hormonal therapy
Patients must be >=  weeks since completing their prior therapy (including surgery, radiation therapy or investigational therapy [including targeted small molecule agents]); all previous clinically significant treatment-related toxicities have resolved to =< grade ; patients must be >=  weeks since prior therapy with an anti-androgen (e.g. casodex, flutamide, enzalutamide or nilutamide)
Received the last administration of an anticancer targeted small molecule therapy (e.g. sunitinib, sorafenib, pazopanib, axitinib, everolimus, temsirolimus, ridaforolimus) =<  days prior to study registration or have not recovered from the side effects of such therapy
Has received prior targeted small molecule therapy, radiation therapy or systemic chemotherapy for urothelial bladder cancer including neoadjuvant chemotherapy\r\n* Prior intravesical chemotherapy or intravesical immunotherapy is permissible, however, no prior intravesical therapy is permitted within  weeks of study enrollment; adjuvant therapy is not permitted